Fig. 1. Graphical representation of the first-line immunotherapy choices in each scenario from survey respondents felt additional immunosuppression would be appropriate. There were clear prefernces for first-line immunosuppressant choices that differed between scenarios. Scenario 6 is a possible exception as there was less consistentcy in first-line treatment choice.


A. All respondents   **B. Experts**   **C. Non-experts**

Fig. 2. Cross-tabulation matrix representing the inter-relationship between treatment choices displayed as a matrix. The absolute number of times a treatment was selected is represented visually as arcs connecting treatments chosen by the same respondent. Wide bands demonstrate that the combination of agents was selected many times. Arcs reconnecting with the same drug demonstrate that the agent was selected by the respondent in more than one scenario with, wide bands again suggesting the agent was selected by many respondents in more than one scenario.
CycloP: cyclophosphamide; HCQ: hydroxychloroquine; IVIg: intravenous immunoglobulin; MTX: methotrexate; MMF: mycophenolate mofetil; PEX: plasma exchange; Ritux: Rituxim.